Prognostic factors in lung cancer patients with lung adenocarcinoma who received chemotherapy and EGFR TKI at H. Adam Malik Hospital Medan

Background: Lung cancer has a poor prognosis compared to other types of cancer because of its low survival rate. The management of lung adenocarcinoma includes a chemotherapy approach and targeted therapy with EGFR-TKI, but the patient is still not optimal. This study aims to determine the prognostic factors in lung cancer patients with lung adenocarcinoma who received chemotherapy and EGFR-TKI at H. Adam Malik Hospital, Medan. Method: This is an analytic study with a retrospective cohort design conducted at the Oncology Polyclinic, H. Adam Malik Hospital from January 2017 to December 2019. The subjects were all patients with lung adenocarcinoma who received chemotherapy and EGFR-TKI treatment. Demographic and clinical evaluation data of patients tested with statistics to assess prognostic factors of adenocarcinoma patients who have been treated. Results: The median length of life for patients receiving EFGR-TKI was 9 months (95% CI: 6,866 – 11,134 months). The median length of life of subjects receiving chemotherapy was 10 months (95% CI: 8,923 – 11,077 months) The median PFS of patients receiving chemotherapy was 6 months (95% CI: 4,841 – 7,159 months) and patients receiving EGFR therapy for TKI was 6 months (CI 95%: 4,720 – 7,280 months). A log-rank test showed that there was a significant difference in median PFS between adenocarcinoma patients receiving EGFR TKI and chemotherapy (p = 0.013). Conclusion: A significant difference was found in the median PFS between patients with lung adenocarcinoma who received EGFR-TKI and chemotherapy.